ES2495266B8 - Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer - Google Patents

Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer Download PDF

Info

Publication number
ES2495266B8
ES2495266B8 ES201330187A ES201330187A ES2495266B8 ES 2495266 B8 ES2495266 B8 ES 2495266B8 ES 201330187 A ES201330187 A ES 201330187A ES 201330187 A ES201330187 A ES 201330187A ES 2495266 B8 ES2495266 B8 ES 2495266B8
Authority
ES
Spain
Prior art keywords
igf
diagnosis
reagent
alzheimer disease
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201330187A
Other languages
English (en)
Other versions
ES2495266A1 (es
ES2495266B1 (es
Inventor
Angel TRUEBA SAIZ
Ignacio Torres Aleman
Carmen CAVADA MARTINEZ
Angel NUÑEZ MOLINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Autonoma de Madrid filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201330187A priority Critical patent/ES2495266B8/es
Priority to EP14751079.6A priority patent/EP2957910A4/en
Priority to US14/767,490 priority patent/US20150374852A1/en
Priority to PCT/ES2014/070103 priority patent/WO2014125150A1/es
Publication of ES2495266A1 publication Critical patent/ES2495266A1/es
Publication of ES2495266B1 publication Critical patent/ES2495266B1/es
Application granted granted Critical
Publication of ES2495266B8 publication Critical patent/ES2495266B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/372—Analysis of electroencephalograms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/384—Recording apparatus or displays specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/40—Animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/42—Evaluating a particular growth phase or type of persons or animals for laboratory research
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)

Abstract

Uso de IGF-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer.#La presente invención se refiere al uso del factor de crecimiento insulínico tipo 1 (IGF-1) como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer, así como a un kit que comprende IGF-1 y un sedante y su uso en el diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer.
ES201330187A 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer Expired - Fee Related ES2495266B8 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201330187A ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
EP14751079.6A EP2957910A4 (en) 2013-02-13 2014-02-12 USE OF IGF-1 AS AN EARLY DIAGNOSTIC AND / OR PROGNOSTIC REAGENT FOR ALZHEIMER'S DISEASE
US14/767,490 US20150374852A1 (en) 2013-02-13 2014-02-12 Use of IGF-1 as a Reagent for Early Diagnosis and/or Prognosis of Alzheimer Disease
PCT/ES2014/070103 WO2014125150A1 (es) 2013-02-13 2014-02-12 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330187A ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Publications (3)

Publication Number Publication Date
ES2495266A1 ES2495266A1 (es) 2014-09-16
ES2495266B1 ES2495266B1 (es) 2015-06-25
ES2495266B8 true ES2495266B8 (es) 2015-11-12

Family

ID=51353508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330187A Expired - Fee Related ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Country Status (4)

Country Link
US (1) US20150374852A1 (es)
EP (1) EP2957910A4 (es)
ES (1) ES2495266B8 (es)
WO (1) WO2014125150A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017470A (en) * 1984-10-29 1991-05-21 Chaovanee Aroonsakul Method of diagnosing alzheimer's disease and senile dementia
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
DE08002964T1 (de) 2001-02-27 2009-09-03 Blanchette Rockefeller Neurosciences Institute Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
CN101102789B (zh) * 2004-12-03 2012-05-30 罗得岛医院 阿尔茨海默病的诊断和治疗
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
EP2115167A1 (en) * 2007-02-08 2009-11-11 Powmri Limited Method of diagnosing a neurodegenerative disease
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2164509A1 (en) * 2007-06-08 2010-03-24 Massachusetts Institute of Technology Igf for the treatment of rett syndrome and synaptic disorders

Also Published As

Publication number Publication date
ES2495266A1 (es) 2014-09-16
EP2957910A4 (en) 2016-09-14
EP2957910A1 (en) 2015-12-23
ES2495266B1 (es) 2015-06-25
WO2014125150A1 (es) 2014-08-21
US20150374852A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
DOP2017000046A (es) Anticuerpos anti tigit
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112017012434A2 (pt) composições de canabinóide microencapsuladas
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
CR20110585A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide
CR20110100A (es) Nuevos derivados de sulfamida sustituida
AR088083A1 (es) USO DE ANTICUERPOS DE UNION A IL-1b
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP13013092A (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
Naziat et al. Confusing genes: a patient with MEN2A and Cushing's disease.
BR112013010169A8 (pt) uso de monascus na produção de ácido orgânico.
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
CL2015001458A1 (es) Composición simbiotica y el uso de la misma.
ES2524164B1 (es) Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide
ES2414290R1 (es) Metodo para el diagnostico y/o pronostico de dano renal agudo
ES2470816B1 (es) Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
ES2495266B1 (es) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
AR095353A1 (es) Compuesto
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2495266

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150625

FD2A Announcement of lapse in spain

Effective date: 20210915